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of Diabetes During Pregnancy
and Congenital Genitourinary Abnormalities
Mounika Parimi1 and Dorothea Nitsch1
1Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UKIntroduction: This study aimed to assess available epidemiological evidence of the relationship between
diabetes during pregnancy and congenital abnormalities of the kidney and the urinary tract (CAKUT).
Methods: POPLINE, MEDLINE, EMBASE, Global Health, CINAHL, and Cochrane Library were searched to
retrieve 6962 articles of which 15 case-control and 11 cohort studies met the inclusion criteria. Random-
effects meta-analysis was performed to estimate the association between CAKUT and diabetes during
pregnancy.
Results: Offspring born to mothers with any form of diabetes in pregnancy had a 50% increased risk of
CAKUT compared with offspring of mothers without diabetes (relative risk [RR], 1.51; 95% confidence
interval [CI], 1.36–1.67). Compared with offspring with nondiabetic mothers, offspring of mothers with pre-
existing diabetes had an almost 2-fold rate of CAKUT (RR, 1.97; 95% CI, 1.52–2.54). Offspring of mothers
with gestational diabetes had a 39% increased risk of CAKUT (RR, 1.39; 95% CI, 1.26–1.55) compared with
offspring of mothers with no diabetes. The subset of studies that adjusted for body mass index (BMI)
before pregnancy showed similar associations. Population attributable risks for gestational diabetes were
estimated to be 3.7% of cases of CAKUT in the United States, 4% of CAKUT cases in the United Kingdom,
with up to 14.4% CAKUT cases in the South Asian population in the United Kingdom.
Conclusion: This study suggests that 2.0% to 3.7% of cases of CAKUT in the United States, and up to 14%
of CAKUT in some populations could be eliminated if gestational diabetes was prevented or eliminated.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C AKUT refers to a range of structural and functionalanomalies of the kidney, collecting system,
bladder, and urethra. The specific cause of CAKUT
remains unknown; however, maternal factors, genetics,
and environmental factors are thought to contribute to
CAKUT.1–4
The incidence of CAKUT was estimated at 4.2 per
10,000 births in Taiwan5 and prevalence of CAKUT is
reported between 0.1% and 0.7%.6,7 Only the most
severe forms are diagnosed during the first year after
birth and less severe cases of CAKUT can be identi-
fied later on during development. CAKUT has severe
implications for the health system, as they can bespondence: Dorothea Nitsch, Department of Non-
unicable Disease Epidemiology, London School of Hy-
and Tropical Medicine, Keppel Street, London WC1E 7HT,
-mail: Dorothea.Nitsch@lshtm.ac.uk
ved 7 August 2019; revised 6 February 2020; accepted 14
ary 2020; published online 28 February 2020responsible for up to 50% of pediatric chronic kid-
ney disease cases.8,9 CAKUT is one of the major un-
derlying diseases in the young adult population on
renal replacement therapy.9,10 Many patients with
CAKUT, even if they are undiagnosed and remain
healthy in adolescence, have an increased risk of end-
stage renal disease during adulthood.11 Therefore,
effective interventions to prevent CAKUT in new-
borns may have the potential to prevent substantive
morbidity. Hence, it is important to understand
whether there are modifiable maternal factors associ-
ated with CAKUT.
Diabetes is accepted as one of the risk factors for
congenital anomalies generally, but evidence of dia-
betes as a risk factor specifically for CAKUT is
sparse.12,13 Diabetes during pregnancy poses health
threats for mother and baby alike, and can be classified
into type 1 diabetes, type 2 diabetes, and gestational
diabetes.14 Uncontrolled diabetes in pregnancy creates
a diabetogenic environment for the fetus, increasing
the risk of adverse pregnancy results includingKidney International Reports (2020) 5, 678–693
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normality, and perinatal mortality.14,15
Worldwide, there has been a reported increase in
women with diabetes mellitus in the childbearing
age.16 Diabetes does not only affect high-income
countries, but its burden is spread across low- and
middle-income countries as well.17 An increase of dia-
betic pregnancies can increase the incidence of adverse
pregnancy outcomes, both for mother and infant.15 It is
therefore important to understand if diabetes in preg-
nancy is associated specifically with CAKUT.
This systematic review aimed to understand the as-
sociation between diabetes during pregnancy and
CAKUT, including an estimate of the number of cases
of CAKUT in the general population that may be
attributed to diabetic pregnancies.METHODS
Literature Search Strategy
One reviewer (MP) searched CINAHL Plus, EMBASE,
MEDLINE, PubMed, POPLINE databases, and the
Cochrane Library, from inception until April 12, 2017.
An updated search in May 2019 identified no addi-
tional studies that could be included in this systematic
review. All hits were considered without a limitation
by year. Each domain of interest (diabetes during
pregnancy, including pre-existing, type 1, type 2 dia-
betes, and gestational diabetes, and congenital abnor-
malities) was searched for with a MeSH term, and a
free-text search. Hits within the domain were com-
bined first, followed by a combination search between
the 2 domains. CAKUT was not specifically used within
the search strategy, as several relevant articles with
results on renal and urogenital abnormalities were
eliminated by a CAKUT-specific narrow search. Rather,
all articles that investigated the role of diabetes on any
form of congenital abnormalities were broadly screened
so that any reported categorical division of abnormality
(i.e., listing numbers on genitourinary abnormalities or
CAKUT) by presence and/or absence of diabetes was
not missed by a narrow search strategy. The search
strategy was slightly modified for the POPLINE
database.
One reviewer (MP) screened titles and abstracts of
articles resulting from the database searches and iso-
lated potentially relevant articles. DN served as a sec-
ond reviewer who screened 100 random abstracts, and
a k statistic was generated to calculate agreement be-
tween the 2 reviewers. The full texts of relevant articles
were examined against the inclusion and exclusion
criteria, and the decision about eligibility was made by
MP. Borderline cases were discussed between DN and
MP.Kidney International Reports (2020) 5, 678–693Inclusion and Exclusion Criteria
Articles from peer-reviewed journals were considered
for the review. Only human studies were included.
Included articles had to refer to some form of diabetes
during pregnancy as a risk factor. All articles referring
to any congenital abnormalities were inspected to
check for a breakdown with specific types of congen-
ital abnormalities, with congenital renal, urogenital,
genital, urinary and/or kidney malformation or ab-
normality or defect as a category. Any type of CAKUT
and chronic kidney disease as outcomes were included.
Observational and intervention studies with a clear,
specified comparison offspring group with CAKUT,
compared within mothers with and without diabetes
were included.
Articles were excluded if they were not published in
a peer-reviewed journal, including conference posters,
abstracts, and letters. Grey literature was not consid-
ered. Studies were excluded if they did not have a
comparison group. Last, studies were excluded if they
were in a language other than English. Animal studies
were excluded.
Data Extraction
Data were extracted using a prespecified extraction
form adapted from PRISMA data extraction tool kits.18
The tool kit was adapted to this systematic review to
include setting, year, study design, study population,
definition of exposure and outcome, ascertainment, and
main results. Data were extracted for pre-existing
diabetes only, for gestational diabetes only, and com-
bined diabetes types (pre-existing and gestational
together).
Quality Assessment
The quality assessment tool was adapted for observa-
tional studies from the Cochrane Collaboration’s tool
for assessing risk of bias in randomized trials.19 Case-
control studies and cohort studies had a slightly
different assessment tool. Studies were evaluated on
participation bias, loss to follow-up (for cohorts), recall
bias (for case-control studies), nondifferential classifi-
cation of exposure and outcomes, observer bias,
ascertainment bias of exposure, and confounding for
relevant maternal characteristics. All categories of bias
in all studies were analyzed and classified as low risk
(green), uncertain or medium risk (yellow), or high risk
(red) of bias with predefined explanations for high and
low risk of bias for each category.
Meta-Analysis
Meta-analysis was performed if the articles contained
an effect estimate (odds ratio [OR] or risk ratio)
comparing occurrence of genitourinary abnormality in679
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maternal diabetes group. Quantitative information for
meta-analysis (RR and 95% CI) was either reported
directly in the study or had to be calculated.
To manually calculate RR and 95% CI, raw numbers
of genitourinary abnormality in nondiabetic control
and exposed diabetic groups were used. When articles
reported individual renal and genital abnormalities, all
relevant abnormalities that fit into the genitourinary
abnormality umbrella were grouped together. The raw
numbers were extracted from the articles and calcula-
tions were made with the risk ratio calculator using the
MEDCALC software online.20 The calculator computes
RR and 95% CI according to Altman.21 The number of
genitourinary abnormalities in the exposed group (i.e.,
the maternal diabetes group) was divided by the total
number of diabetic mothers, and compared with the
number of genitourinary abnormalities in the control
group (i.e., nondiabetic mother group was divided by
the total number in the control group).
If articles reported an RR, then this was used for
meta-analysis, otherwise the manually calculated RR
was used. If an adjusted RR was presented, then this
was used. ORs and risk ratios were combined because
genitourinary abnormalities are rare, and the number
of these abnormalities is small. Therefore, there is no
drastic difference between OR calculation and a risk
ratio calculation.
The RR and the 95% CI were exported to STATA 14
(StataCorp, College Station, TX) and the log of the RR and
the 95% CI were used for random-effects meta-analysis.
A random-effect meta-analysis was performed, as the
studies have slight variations in definitions of outcome,
and therefore the assumption of a single population
giving rise to the separate studies is not met.Sensitivity Analysis for Confounding
In this review, some estimates were crude, others were
adjusted, raising the possibility of residual confound-
ing affecting the final summary measure of association.
From evaluating all studies, maternal age and BMI
were determined to be important confounders in the
study. Therefore, all studies were accessed for the
likelihood for confounding when comparing genito-
urinary abnormalities in the case group and the control
group.
Studies were classified to have minimal confounding
when:
(i) Studies at least adjusted for maternal age. In addi-
tion, studies needed to adjust for all variables in
multivariate analysis that were different between
cases and controls in the univariate analysis (but
not on the causal pathway).680(ii) For studies that adjusted the estimate for the asso-
ciation of all congenital abnormalities with diabetes
for confounders, and for which there was no dif-
ference found between the crude and adjusted ra-
tios or rates. This situation arose for studies with
small counts that did not allow adjustment for as-
sociations seen for specific subgroups. Here we
assumed that any confounding structure in the data
would apply for the rate ratio for genitourinary
anomalies as seen for the total sample.
All articles that fulfilled 1 of the 2 preceding criteria
were used for a random-effects meta- analysis,
considering only articles with minimal confounding.
In addition, articles that adjusted for BMI were
combined in a meta-analysis.
Population Attributable Risk
Population attributable risk (PAR) of gestational dia-
betes for CAKUT was calculated based on prevalence
estimated for diabetes during pregnancies and the most
conservative estimate of RR from the meta-analysis (RR,
1.42). Because meta-analysis and sensitivity analysis
indicated strong evidence for an association between
gestational diabetes and congenital genitourinary ab-
normalities, PAR was calculated for gestational diabetes
only. In addition, the RR used for calculations of PAR
was from the meta-analysis conducted with studies that
attempted to adjust for confounding, as this was the
most conservative estimate.
Because there is no clear report on the true global
prevalence of gestational diabetes and because rates of
gestational diabetes differ according to population
factors and diagnostic factors, PAR was calculated for
specific countries.22,23 Based on available prevalence
data, PAR was calculated for the United States, United
Kingdom/Ireland (stratified by white population and
South Asian population), and India.
RESULTS
After a rigorous systematic search, 15 case controls
studies and 11 cohort studies met the inclusion/exclu-
sion criteria and were included in the systematic review
(Figure 1). Comparison of inclusion/exclusion of 100
random articles by the second reviewer (DN) compared
with the first reviewer resulted in Cohen’s k ¼ 1 rep-
resenting 100% consensus between both reviewers.
Assessment of Included Studies
A detailed breakdown of the case-control and cohort
studies is presented in Tables 15,24–37 and 2.13,15,38–47
All included cohort studies were from high-income
country settings and covered the period between
1984 and 2010 and included the total sample size of
6,053,931 mothers with and without diabetes among 9Kidney International Reports (2020) 5, 678–693
Figure 1. Flow diagram for selection of articles included in the systematic review. The initial database searches identified 8914 articles, of
which 26 articles were included in the systematic review (15 case controls and 11 cohort studies). CAKUT, congenital abnormalities of the
kidney and the urinary tract.
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studies were regionally based, 2 were hospital
based,13,40 and 1 study was based nationally.43 Ten
comparative cohort studies compared pregnancy out-
comes in cohort of diabetic mothers with a cohort of
nondiabetic mothers. The comparison of interest was
the frequency of CAKUT in offspring of mothers with
diabetes compared with the frequency of CAKUT in
offspring of mothers with no diabetes during
pregnancy.13,15,32,39,42–44 One study compared the in-
fants born to women with diabetes with infants in the
general (source) population and compared the fre-
quency of renal abnormalities between these cohorts.45
One study was not included in meta-analysis, as a
comparative nondiabetic population was not defined.40
The settings of the case-control studies were from a
mixture of high-income countries (Europe, Canada, and
the United States) and middle-income countries
(Turkey and Taiwan). Eleven studies were population
based and 4 were hospital based. Studies covered the
period between 1980 and 2011. Twelve case-control
studies first sampled cases (i.e., children, newborns,
or in some cases fetuses with CAKUT). These cases were
then compared with controls (children, newborns, or
fetuses without CAKUT) with regard to the frequency
of maternal diabetes in pregnancy. There was 1 study
that sampled based on exposure status among a pop-
ulation of CAKUT patients. Mothers of CAKUT patients
with diabetes were cases, and mothers of CAKUT pa-
tients without diabetes were the controls. This study
was not included in the meta-analysis.30 There were 2
population-based case-control studies that included allKidney International Reports (2020) 5, 678–693newborns with CAKUT from the population, and the
frequency of mothers with and without diabetes was
calculated among children with CAKUT.32,33 Because
these were population based, these 2 studies were
included in the meta-analysis. The total number of
cases was 17,013 across 13 case-control studies. This
calculation does not include 2 studies: 1 that was
excluded from meta-analysis and 1 study did not report
on the specific n for case and control groups for the all
abnormality subgroup, but rather reported the OR
only. More information on specific counts among case
and control groups among diabetic and nondiabetic
mothers is included in Table 1.
Qualitative Assessment of All Included Studies
The quality of the studies was variable: Figure 2
summarizes the qualitative assessment of case-control
and cohort studies according a colour scheme: red to
indicate a high risk of bias, yellow for uncertain risk,
and green for low risk of bias. An explanation of the
reasoning for specific ratings and the scale for assess-
ment is included in the supplementary materials
(Supplementary Table S1A–C).
Almost all studies had no evidence of recall or
observer bias. Nondifferential misclassification of
exposure (i.e., either missing diagnosis of diabetes or
wrong categorization of the type of diabetes) was a
problem in some studies. Nondifferential misclassifica-
tion of the outcome (i.e., wrongly diagnosed congenital
genitourinary abnormality) was a problem in studies
with no strict diagnostic criteria. Differential ascer-
tainment bias arises if pregnant women with diabetes681
Table 1. Study characteristics of case-control studies
Study details Exposure Outcome
Study/ paper Date Setting Case definition Control definition Exposure definition Type of diabetes Ascertainment D ition
Abnormality
specification Ascertainment
Banhidy24 2010 Hungary Cases were children
diagnosed with CAs from birth
until 1 postnatal yr (including
deaths and termination) from
the HCAR (1980–1996)
n ¼ 3555
Controls were newborn infants
without any CA selected by National
Birth Registry matched 2 controls
per case (sex, birth wk, district of
residence)
n ¼ 38,151
International
Consensus, glucose
serum test high serum
glucose level þ
diagnostic glucose
tolerance test
T1D, T2D,
and GDM
Medically recorded
data obtained from
logbooks
CA were fferentiated
into g ps lethal,
severe nd mild;
single multiple
Renal agenesis/
dysgenesis;
obstructive
urinary CA,
hypospadias
Mandatory notification by
physicians to HCAR of CA from birth
until end of first postnatal yr or
autopsy reports of infant deaths
Correa25 2008 United
States: 10
states
covered
under the
NBDPS
Live births, stillbirths, or
terminations with CA from
NBDPS between 1997 and
2003; only known-cause
abnormalities were excludeda
n ¼ 51
Live-born infants without birth
defects randomly selected from birth
certificates or hospitals
n ¼ 4895
Physician-diagnosed
diabetes but reported
by the mother
PGDM, GDM Self-reported diabetes
status
Isolate r multiple
defects ssified by
clinica eneticists
based reviews of
clinica formation
Bilateral renal
agenesis/
hypoplasia
Obtained from NBDPS data based
on clinical geneticists’ diagnosis
(cases) controls randomly selected
from birth certificates or hospitals
Dart26 2015 Manitoba,
Canada
Infants older than 20 weeks’
gestational age born in
Manitoba with at least 1 ICD
code for CAKUT (stillborn
infants included); infants were
both between fiscal yr 1996/
1997 and 2009/ 2010
n ¼ 945
Infants without ICD code for CAKUT
or other CA in first yr of life, matched
5 controls:1 case (gestational age,
sex and birth year); excluded if 2 yr
of follow-up not available
n ¼ 4725
ICD codes, PGDM:
ICD code for DM over
2-yr period before
pregnancy
GDM, PGDM (T1Dþ
T2D)
ICD codes; forms and
Diabetes Education
Resource for Children
and Adolescents,
drug data
CAKUT m ICD-9
and codes
CAKUT Hospital records for first 2 yr of life
Davis27 2010 Texas
(Houston/
Galveston
area) Texas
Health
Service
Region 6
Deliveries with renal agenesis/
dysgenesis identified from the
Texas Birth Defects Registry
within first postnatal yr (from
births after 20 weeks’
gestation) from 2000–2002
n ¼ 89
Controls were frequency matched
using cumulative incidence
sampling 4 controls:1 case
(delivery yr, and vital status at
delivery)
n ¼ 356
DM not specified No distinction between
types of GDM or PGDM
Birth certificates and
fetal death records
Deliver with renal
agenes ysgenesis
Renal agenesis/
dysgenesis
Texas birth defect registry
(surveillance system through 1 yr
of life)
Frías28 2007 Spain (80
hospitals
included in
study)
1976–2005
Cases are identified by
pediatrician examination of all
newborns in participating
hospitals as those with major
or minor CA
n ¼ 1057
Children born between 1976 and
2005; were included in the study
only if data on maternal glucose
tolerance were available
n ¼ 30,009
Maternal Glucose
Tolerance Status
PGDM and GDM Glucose challenge
test performed
between 24 and 28
wks of gestation
Coding cording 2
lev and 3
sublev modified
ICD-8 es along
with ditional
spe ations
MDK Examination by pediatrician: CA
(cases) identified using modified
version of ICD-8; next child born
nonmalformed of same sex in
same hospital was classified as
control
Groen in ’t
Woud29
2016 Nijmegen,
Netherlands
Patients diagnosed with renal
agenesis, renal dysplasia,
ureteropelvic junction
obstruction, duplex collecting
system, multicystic dysplastic
kidney, PUV, and/or VUR
treated at Radboud Medical
Center from 1981 onward,
genetic and chromosomal
anomalies excluded
n ¼ 553
Controls born between 1990 and
2011 were randomly sampled from
39 municipalities throughout the
Netherlands and controls with major
CA excluded
n ¼ 2116
Assumed to be
physician-diagnosed
diabetes but reported
by mother
Pre-existing
(diagnosed up until
10th wk of pregnancy)
or diabetes during
pregnancy (diagnosed
after 10th wk)
Questionnaire filled
out by parents of
patients in AGORA
data bank
CAK (from
2004) other renal
abnorm ities until
2004 part of
A RA
CAKUT Medical review of cases from
AGORA by pediatric nephrologist,
urologist, and/or clinical geneticist
(Continued on next page)
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Table 1. (Continued) Study characteristics of case-control studies
Study details Exposure Outcome
Study/ paper Date Setting Case definition Control definition Exposure definition Type of diabetes Ascertainment Definition
Abnormality
specification Ascertainment
Garne30,b 2011 18 regions in
Europe
EUROCAT registry was used;
cases are CA with mother who
has PGDM; live births, fetal
deaths and terminations were
included
n ¼ unknown
Malformed infants or fetuses from
EUROCAT whose mothers were
nondiabetic
n ¼ unknown
ICD-10 codes and
other written text
associated with
maternal diabetes
PGDM As recoded in the
EUROCAT database,
the registry was
based on multiple
sources of
information (birth,
death certificates,
terminations of
pregnancy, hospital
records, etc.)
ICD-9 or ICD-10 with
BPA extensions;
subgroups of
anomalies are based
on ICD BPA codes
Isolated renal
anomalies
As recoded in the EUROCAT
database based on multiple
sources of information (birth, death
certificates, terminations of
pregnancy, hospital records, etc.)
Nielsen31 2005 Hungary-
from HCAR
CA including malformed
fetuses after termination of
pregnancy in second and third
trimesters, stillborn fetuses,
live-born infants diagnosed
with CA until first yr of life
between 1980 and 1996.
Some mild CA and syndromes
of known origins were
excluded
n ¼ 2657
2 newborns per case without CA
were chosen as controls (matched
for sex, birth week, district of
parents’ residence)
n ¼ 38,151
Pre-gestational
insulin-treated DM if
insulin use was
recorded in the log
book before or during
1st trimester
PGDM Questionnaire and
antenatal logbooks
(written record of
disease and drugs
given by obstetrician)
Classification made
by HCAR
Renal agenesis/
dysgenesis and
obstructive CA
of the urinary
tract
Physician-reported stillborn, infant
deaths, termination, included
Newham32,c 2013 North of
England
All singleton births, stillbirths,
miscarriages, or terminations
from 1996–2008 with CA,
chromosomal anomalies
excluded n ¼ 986
No control for this study, as this
was a population-based case-
control study n ¼ 6162
Pre-gestational
diabetes
From NorDIP records ICD-10 classification
and categorized
according to
EUROCAT criteria
From NorCAS Urinary
abnormalities
Examination by physician after
birth
Postoev33 2016 Murmansk
County,
Russia
Newborns (more than 22 wks
of gestation) with CAKUT
recorded in the MCBR from
2006 to 2011
n ¼ 203
Newborns without CAKUT from the
birth registry (2006–2011)
n ¼ 50,723
DM and GDM as
diagnosed by
physicians
DM and GDM From the MCBR
database
According to ICD-10 CAKUT From the MCBR database
Ramos-Arroyo34 1992 Spain CA in live births identified by
physician diagnoses at
participating hospitals within 3
days of life between 1976 and
1985 n ¼ N/A
One control per case, next
nonmalformed live birth of the same
sex born in same hospital n ¼ N/A
Insulin-dependent or
non–insulin-
dependent- chronic,
or GDM when first
diagnosed during
pregnancy
Insulin-dependent and
non–insulin-dependent
DM and GDM
From interview with
mother
CA diagnosed by
experienced
physician
Genitourinary Examination by physician after
birth
Shnorhavorian35 2011 Washington
State, USA
Children with urinary
anomalies (ICD-9) at birth
through 5 yr of age diagnosed
between 1987 and 2007,
chromosomal anomalies were
excluded
n ¼ 4248
Infants without urinary tract
anomalies selected from birth
records and frequency matched 4
controls:1 case (matched for
birth yr) n ¼ 17,258
DM recorded in WSBR
as pre-existing
medical condition so
physician diagnosis
PGDM and GDM As recorded in WSBR Urinary anomalies
from ICD-9
CUTA; but in
meta-analysis
kidney
anomalies is
used
From the WSBR and linked with
Washington CHARS database
Soylu36 2017 Turkey Children 0–18 yr with prenatal
or postnatal CAKUT diagnosis,
chromosomal renal anomalies
excluded n ¼ 140
Children 0–18 yr having a urinary
tract infection, without CAKUT,
matched 1:1 n ¼ 140
Gestational diabetes
recorded by medical
professional
GDM Hospital files of all
cases examined
retrospectively
(antenatal data from
routine questionnaire
during clinic visit)
Uncertain— not
reported
CAKUT Uncertain
(Continued on next page)
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684may be monitored closely for presence of abnormalities
in their offspring in some settings. This was also a
concern in studies in which terminations of pregnancy
and miscarriages were not considered in analysis and
where there was no follow-up of children after birth;
CAKUT can be diagnosed after birth in the first few
years of life.
Adjustment for confounding was variable among
studies. Because of the small numbers of CAKUT in the
studies, adjusting for confounding was difficult. Some
studies adjusted for confounding factors in analyses of
risk factors for overall congenital abnormalities but
only reported crude data for CAKUT specifically.
Maternal age and obesity can all be considered poten-
tial confounders because of their association with both
diabetes and congenital abnormalities.45 These were
accounted for in studies with larger study populations.
Association Between Diabetes and Congenital
Genitourinary Abnormalities
Figure 35,24–29,33,35,37,41,44–46 shows the relative risk
(RR) and 95% CIs from the combination of cohort
studies and case-control studies investigating the rela-
tionship among all diabetes during pregnancy and
CAKUT and their pooled random-effects estimates. The
estimated values indicate an increased risk of CAKUT
associated with any form of diabetes in pregnancy (i.e.,
pre-existing diabetes or/and gestational diabetes).
Compared with nondiabetic pregnancies, women with
diabetes have a higher risk of giving birth to infants
with CAKUT. The pooled RR of CAKUT among mothers
with any form of diabetes (pre-existing and gestational)
was 1.51 (1.36–1.67), and the I2 value (measure of
variation across studies) was 25.3% (P ¼ 0.182), indi-
cating low heterogeneity of findings. The funnel plot
suggested minimal evidence of publication bias
(Supplementary Figure S1A).
Some studies specifically investigated the type of
diabetes (pre-existing or gestational) in pregnancy,
allowing stratified meta-analysis is this systematic re-
view. Analysis restricted to mothers with pre-existing
diabetes (i.e., diabetes known before pregnancy)
resulted in a pooled RR of 1.97 (1.52–2.54)
(Figure 4b13,15,38,40–46). However, there was evidence of
high heterogeneity in the meta-analysis and pooling of
results for pre-existing diabetes only and CAKUT (I2 ¼
70.2%, P < 0.001), and evidence of publication bias in
the corresponding funnel plot (Supplementary
Figure S1B). In contrast, when restricting analyses to
studies that investigated the link between mothers
with gestational diabetes and CAKUT, the pooled RR
was 1.39 (1.26–1.55) (Figure 4a5,24–37), with low het-
erogeneity of results in the meta-analysis (I2 ¼ 0.0%,
P ¼ 0.884) and only minimal/no evidence ofKidney International Reports (2020) 5, 678–693
Table 2. Study characteristics of cohort studies
Study details Exposure Outcome
Study/ paper Date Setting
Population (no., age,
inclusion/exclusion) Exposure definition Type of diabetes Ascertainment Definition
Abnormality
specification Ascertainment
Agha38 2016 Ontario, Canada All children born in hospital in
Ontario, Canada between
1994 and 2009
n ¼ 2,058,755
According to physician
diagnosis
PGDM Ontario Diabetes Database
collection from physician
claims and hospital discharge
abstracts
ICD-9 and -10 codes Renal defects Discharge Abstract Database
Bell39 2012 North of England All singleton pregnancies in
northern UK resulting in live
birth, stillbirth, late fetal loss,
or termination of pregnancy
following prenatal diagnosis of
a fetal abnormality (1996–
2008) who are also covered
by registry data from CA
register and diabetes in
pregnancy register
n ¼ 401,149
According to the NorDIP
survey- HbA1c levels
PGDM (at least
6 mo before
conception)
NorDIP, which records details
of all known diabetic
pregnancies irrespective of
outcomes
According to the ICD-10 and
categorized using EUROCAT
criteria by group, subtype, or
syndrome
Urinary NorCAS collecting information
on all cases of CA, fetal loss,
termination of pregnancy until
12 yrs of age
Garcia-Patterson40,a 2004 Barcelona, Spain Infants born between 1/1986
and 7/2002 at 22 complete
gestation wks or later of
mothers with documented
diagnosis of GDM
n ¼ NA
Third workshop
conference on GDM
criteria
GDM Hospital records Major CA: life-limiting, caused
cosmetic or functional
impairment, or needed surgery
Renal/ urinary Examination by neonatologist
followed by image studies if
CA was suspected
Janssen41 1996 Washington
State, USA
All certificates indicating
diabetes in mothers from
1984–1991 in Washington
State; comparative cohort
consisted of women with no
diabetes; Down syndrome was
excluded, live births only were
considered n ¼ 19,314
Physician diagnosis as
indicated in certificate of
live births
GDM, PGDM From Washington State
certificates of live births
Physician-diagnosed: no
criteria indicated
Malformed genitalia,
renal agenesis, and other
urogenital anomalies
From Washington State
certificates of live births
Liu42 2015 Canada Live births in Canada
(excluding Quebec) for fiscal
yr 2002/03– 2012/13,
stillbirths were excluded,
inclusion criteria included >22
weeks’ gestation and >500 g
birth weight
n ¼ 2,839,680
Pre-pregnancy DM
according to ICD-10
Pre-pregnancy
DM: T1D and T2D
From the Discharge Abstract
Database
Medical record of CA
according to ICD-10
Genitourinary From Discharge Abstract
Database
Moore43 2000 USA 10/1984–06/1987: women
from 100 obstetric practices
who underwent 2nd trimester
amniocentesis or alpha-
fetoprotein screening studies
n ¼ 22,951
National standards for
diabetes classification
T1D, T2D, GDM
For urogenital CA,
only GDM
information
available
Telephone interview between
15th and 20th mo of
gestation, specific time of
onset and other detailed
questions about diabetes
control and medication
6-Digit code list from Centers
for Disease Control and
Prevention and exclusion of
nonchromosomal
abnormalities
Urogenital Outcome questionnaire
mailed to delivering
physicians (77% response
rate) and the rest completed
by mother with clarification
when necessary
Peticca44 2009 Ontario All obstetric deliveries in
Ontario province between 04/
2005 and 05/2006, with
voluntary participation in
database n ¼ 120,604
Diabetes was recorded as
part of database by
medical professionals
GDM, T1D, T2D From Ontario Niday Perinatal
Database, voluntary
participation from sites; data
acquired by nurse or staff and
put into database
Recorded in the database by
professional/midwife using
hospital codes
Genitourinary From the database
(Continued on next page)
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Table 2. (Continued) Study characteristics of cohort studies
Study details Exposure Outcome
Study/ paper Date Setting
Population (no., age,
inclusion/exclusion) Exposure definition Type of diabetes Ascertainment Definition
Abnormality
specification Ascertainment
Sharpe45 2005 South Australia All singleton births (alive and
stillbirths) in south Australia
between 1986 and 2000
>400 g or >20 weeks’
gestation, terminations not
included
n ¼ 282,260
Blood glucose levels and
diagnostic criteria in the
hospitals
GDM, PGDM Department of Health’s POSU Coded according to ICD-9 with
British Pediatric Association
Perinatal Supplement
Urogenital From the SABDR collecting
until age 5 yr
Sheffield13 2002 Texas, USA All women delivering at
Parkland hospital in Texas for
the study period were included
n ¼ 145,196
From 1991–1996 some
at-risk women were
systematically screened
for GDM; between 1996
and 2001 all women were
screened
PGDM Glucose tolerance test
interpreted according to
National Diabetes Data Group
Diagnosed by neonatal faculty
and confirmed by geneticist
Renal Newborn nursery hospital
records at time of discharge
or stillborn records
Vinceti46 2014 Italy Deliveries (still and live births)
recorded in the National Health
service for the Emilia-
Romagnia region between 01/
1997 and 12/2010 (only
those included in the Region
Birth Defects Registry)
n ¼ 12,917
GDM and PGDM as
diagnosed by physician
listed in the registries
PGDM (T1D, T2D)
and GDM
First ascertainment from
hospital discharge record from
National Health Service, Birth
Certificate Archives of PGDM;
ascertainment was validated
with drug records to confirm
classification
ICD-9 Genitourinary Emilia-Romagna Region Birth
Defects registry
Yang15 2006 Nova Scotia, Canada All diabetic and nondiabetic
mothers between 01/1988
and 12/2002; pregnancies
reaching 20 weeks of
gestation and 500 g were
considered; terminations were
not included
n ¼ 151,105
Defined according to
White’s classificationb
PGDM Abstracted from standardized
antenatal record collected at
first antenatal visit: Nova
Scotia Perinatal Database
Major CA defined as lethal, life-
shortening, life-threatening,
requiring major surgery, or
affecting quality of life
Genito-urinary From the Nova Scotia Atlee
Perinatal Database
CA, congenital abnormalities; DM, diabetes mellitus; EUROCAT, European network of population-based registries for the epidemiological surveillance of congenital anomalies; GDM, gestational diabetes mellitus; HbA1c , hemoglobin A1C; ICD,
International Classification of Diseases; NorCAS, Northern Congenital Abnormality Survey; NorDIP, Northern Diabetes in Pregnancy Survey; PGDM, pre-gestational diabetes mellitus; POSU, pregnancy outcome statistics unit; SABDR, South Australian
Births Defect Register; T1D, type 1 diabetes; T2D, type 2 diabetes.
aThis study was not included in the systematic review, as a control group of women without diabetes was not clearly defined and the rate of congenital abnormalities among the diabetic group was not compared with congenital abnormalities in the
nondiabetic group.
bWidely used to assess maternal and fetal risk and differentiates between GDM and pre-existing diabetes; named after Priscila White.47
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Figure 2. Quality assessment of all included (a) case-control studies and (b) cohort studies. Fifteen case-control studies (a) and 11 cohort
studies (b) were qualitatively assessed for their risk of bias and confounding and ranked as red for high risk, yellow for uncertain risk, and green
for low risk.
M Parimi and D Nitsch: Diabetes During Pregnancy and CAKUT CLINICAL RESEARCHpublication bias according to the funnel plot
(Supplementary Figure S1C).
Sensitivity Analysis: Adjustment for
Confounding
Two sensitivity analyses were performed to investi-
gate the role of confounding on results. An in-depth
analysis of confounders from each study, including
comparison of crude and adjusted ORs (where
available), is indicated in the supplementary
materials (Supplementary Table S2, Supplementary
Figure S2A–C and Supplementary Figure S3A,B).
First, we restricted the analyses to studies that
adjusted for locally determined confounding variables.
Depending on context, every study had a different set
of possible confounders that investigators choose to
adjust for. Maternal age was the only variable that was
constantly adjusted among all studies. Restricting the
analysis to studies that attempted to adjust for con-
founding slightly increased the summary measures of
the association of any diabetes, pre-existing diabetes,
and gestational diabetes with CAKUT compared withKidney International Reports (2020) 5, 678–693the summary measure when all the studies were
included (Table 3).
A second analysis was restricted to studies that
specifically adjusted for BMI as a confounding vari-
able. Three studies evaluated the difference in rates of
CAKUT in normal and high maternal BMI groups and
found little to no evidence of difference in rates of
abnormalities between the groups.29,41,44 Hsu et al.37
reported a difference between crude and adjusted ra-
tio after adjustment for maternal BMI in pre-
gestational diabetic women, and a small difference in
gestational diabetic women. A positive association
between chronic kidney disease in infants and
maternal BMI, after adjusting for diabetes and hy-
pertension is also reported.37 One study found a dif-
ference in OR of CAKUT in gestational diabetic women
in the second and third tertile of BMI compared with
reference first tertile of BMI, concluding that pre-
pregnancy BMI is a predictive variable of renal/uri-
nary abnormalities.21 There were only 2 studies that
reported specific ORs of CAKUT after adjustment for
maternal BMI that could be combined in meta-analysis687
Figure 3. Forest plot of relative risk (RR) of congenital abnormalities of the kidney and the urinary tract (CAKUT) with all maternal diabetes.
Fourteen studies5,24–29,33,35,37,41,44–46 that compare CAKUT in offspring of mothers with any diabetes type and CAKUT in mothers with no diabetes
are summarized here. The summary measure of association is RR, 1.51 (95% confidence interval [CI], 1.36–1.67). ES, effect estimate.
CLINICAL RESEARCH M Parimi and D Nitsch: Diabetes During Pregnancy and CAKUT(OR 2.71 [0.77–9.59]) (Table 3).25,37 Adjusting for BMI
did not attenuate the association between gestational
diabetes and CAKUT.
Population Attributable Risk
PAR was calculated based on the most conservative
estimate of association between gestational diabetes and
CAKUT, after attempting adjustment for known con-
founders (RR, 1.42). Table 423,48–50 indicates PAR of
gestational diabetes for CAKUT based or prevalence
estimates in the United States, the United Kingdom
(white and South Asian population), and in India.
Assuming that gestational diabetes is causal for
CAKUT, estimates suggest that approximately 2.0% to
3.7% of cases of CAKUT in the United States, and 3.3%
to 4.0% of cases of CAKUT in the United Kingdom
could be prevented if gestational diabetes was elimi-
nated. In the South Asian population in the United
Kingdom, this estimate can be as high as 14.4% (ac-
cording to the Atlantic Diabetes in Pregnancy [ADIP]
database). Using 2 estimates of reported prevalence of
gestational diabetes in India, between 6.5% and 12.5%
of CAKUT cases could be prevented if gestational dia-
betes was eliminated.
DISCUSSION
This systematic review and meta-analysis, combining
case-control and cohort studies worldwide, provides
evidence of a potential link between and diabetes
during pregnancy and CAKUT: compared with688nondiabetic mothers, women with any type of dia-
betes during pregnancy are 50% more likely to give
birth to infants with congenital genitourinary abnor-
malities, the risk is 2-fold in women with pre-
gestational diabetes and increased by 40% in women
with gestational diabetes. Analyses restricted to
studies that control for confounders did not change
the results drastically.
These results are worrisome, especially as there has
been an increase in diabetes incidence throughout the
world, affecting low-, middle-, and high-income
countries. The link between diabetes and congenital
abnormalities overall has been investigated and is well
established, and therefore finding an association be-
tween maternal diabetes and CAKUT in the offspring is
plausible.12,13 Calculating attributable fractions
assuming that diabetes causes a 40% increase in the
incidence of CAKUT concludes that approximately
1.9% to 3.7% of CAKUT in the United States and 4.1%
of CAKUT in the United Kingdom/Ireland may be
associated with gestational diabetes. This estimate is
much higher in the South Asian population in the
United Kingdom, estimating 14.4% of CAKUT associ-
ated with gestational diabetes. There is a potential that
PAR is much higher, given that the RR for the asso-
ciation between any diabetes type in the mother and
CAKUT is estimated to be at least 50% higher and the
prevalence of women with any diabetes at pregnancy
will automatically be higher than the prevalence of
gestational diabetes only.Kidney International Reports (2020) 5, 678–693
Figure 4. Forest plot of relative risk (RR) of congenital abnormalities of the kidney and the urinary tract (CAKUT) among (a) gestational diabetes
and (b) pre-existing diabetes. Fourteen studies5,24–37 that compare CAKUT in offspring of mothers with gestational diabetes (a) and 17
studies5,13,15,38,40–46 of mothers with pre-existing diabetes (b), to CAKUT in mothers with no diabetes are summarized here. The summary
measure of association is RR, 1.39 (95% confidence interval [CI], 1.26–1.55) for gestational diabetes and RR 1.97 (95% CI 1.52–2.54) for pre-
existing diabetes. ES, effect estimate.
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Table 3. Summary RR of association of diabetes and CAKUT in all studies and studies considered in sensitivity analysis
All studies
Studies that attempted to control for
confounding Studies that adjusted for BMI
RR (95% CI) I 2 (P value) RR (95% CI) I 2 (P value) RR (95% CI) I 2 (P value)
Any diabetes 1.51 (1.36–1.67) 25.3% (0.182) 1.56 (1.26–1.94) 13.1% (0.327) —
Pre-existing diabetes only 1.97 (1.52–2.54) 70.2% (0.000) 2.10 (1.75–2.52) 44.6% (0.071) 2.71 (0.77–9.59) 74.9% (0.019)
Gestational diabetes 1.39 (1.26–1.55) 0.0% (0.884) 1.42 (1.22–1.64) 0.0% (0.867) 1.50 (1.16–1.93) 74.9% (0.019)
BMI, body mass index; CAKUT, congenital abnormalities of the kidney and the urinary tract; CI, confidence interval; RR, relative risk.
CLINICAL RESEARCH M Parimi and D Nitsch: Diabetes During Pregnancy and CAKUTThis study supports the pathophysiology of CAKUT
in the context of hyperglycaemia studied in animal
models, which suggests that maternal hyperglycaemia
adversely effects kidney development of the fetus. In
rats, number of nephrons formed during kidney
development in pups of diabetic female rats was
significantly reduced due to hyperglycemia.51 The 2
key events in kidney development, ureteric branching
morphogenesis and nephrogenesis, both are adversely
affected by hyperglycemia in diabetic mouse models.52
Maternal diabetes during pregnancy can cause changes
in gene expression levels in the mouse embryo, dis-
rupting the epithelial layers and mesenchymal cell in-
teractions during kidney development, which can
cause CAKUT.53–55
A strength of this study includes an inclusive and
wide search. A systematic search of reported literatureTable 4. PAR % of CAKUT due to gestational diabetes in the United
Kingdom, United States, and India
Country Prevalence of GDM (%) PAR (%)
United Statesa
CDC (national study) 4.6–9.2 1.9–3.7
United Kingdom/Ireland (all)b
ADIP 10.19 (9.43–10.95) 4.1 (3.8–4.4)
BiB 8.15 (7.62–8.67) 3.3 (3.1–3.5)
Warwick 8.68 (8.0–9.36) 3.5 (3.3–3.8)
United Kingdom/Ireland (white)
ADIP 8.6 (6.1–11.1) 3.5 (2.5–4.5)
BiB 4.9 (1.9–7.9) 2.0 (0.8–3.2)
Warwick 8.1 (5.2–11.0) 3.3 (2.1–4.4)
United Kingdom/Ireland
(South Asian)
ADIP 39.1 (28–50) 14.41 (10.5–17.4)
BiB 10.8 (8.1–13.4) 4.3 (3.3–5.3)
Warwick 10.8 (5.1–16.5) 4.3 (21.0–6.5)
India
Chennaic 16.6 6.5
North Indiad 35 12.8
ADIP, Atlantic Diabetes in Pregnancy study; BiB, Born in Bradford Study; CAKUT,
congenital abnormalities of the kidney and the urinary tract; CDC, Centers for Disease
Control and Prevention; GDM, gestational diabetes mellitus; PAR, population attributable
risk; Warwick, Warwick/Coventry Cohort Study.
aMixed diagnostic criteria from 3 primary criteria used in the United States are by the
National Diabetes Data Group, Carpenter and Coustan, and the International Associa-
tion of Diabetes and Pregnancy Study Groups (IADPSG).48
bPrevalence data from systematic review; diagnostic criteria used for GDM: World
Health Organization (WHO) 1999.23
cStudy based on one government hospital in Chennai; diagnostic criteria for GDM: WHO
1999.49
dPopulation-based screening study in North India; diagnostic criteria for GDM: WHO
2013.50
690including studies that did not specifically focus on
renal abnormalities but reported congenital abnormal-
ities for a range of organ systems was conducted. These
studies would have been missed by a narrower search.
Other study strengths include the inclusion of both
case-control studies and cohort studies. Estimates of RR
were presented for all diabetes and further stratified by
gestational and pre-gestational diabetes. A thorough
assessment of bias and confounding is included, with
sensitivity analysis considering only those that
adjusted for BMI (an important confounder).
A limitation of the study is that studies that were
published in languages other than English were
excluded. Of 6962 unique studies considered for this
study, only 9 articles (0.1%) were published in a lan-
guage other than English. Translated abstracts of these
articles revealed that CAKUT was not identified as an
outcome. Therefore, it is likely that the studies pub-
lished in a language other than English would have
been excluded from the meta-analysis anyway.
A concern is that studies were of variable quality.
First, there remains a concern of ascertainment bias,
that in some settings, women who have diabetes in
pregnancy undergo more thorough screening for ab-
normalities in their offspring. However, Newham
et al.32 showed no difference in antenatal detection of
CAKUT between women with and without pre-
gestational diabetes. In addition, when scrutinizing
the outcome definitions for the included studies, the
clear majority are from large birth registries with
thorough outcome ascertainment for severe and
symptomatic forms of renal and urological abnormal-
ities in early life. The case-control studies included
CAKUT diagnosed after the first year of birth and
therefore addressed this issue somewhat. The outcomes
included are a heterogeneous mix including severe
forms of CAKUT, including renal agenesis. However,
considering the patho-mechanism of elevated glucose
levels leading to organ abnormality, it would not be
surprising to find a heterogeneous mix of outcomes, as
has been reported for the effect of diabetes on
congenital abnormalities overall.
Voluntary terminations of pregnancy were included
in 6 studies among the 26 studies in the systematic
review, as information on terminations were notKidney International Reports (2020) 5, 678–693
M Parimi and D Nitsch: Diabetes During Pregnancy and CAKUT CLINICAL RESEARCHaccessible in most of the data sources. Therefore, it is
likely that our systematic review underestimates the
rate of CAKUT, especially in more recent years during
which improved screening and detection methods may
have led to greater number of voluntary terminations.
The likelihood of detecting CAKUT in diabetic
pregnancies is probably higher compared with the
nondiabetic population, as the likelihood for screening
might be greater among the diabetic population.
Therefore, the likelihood of detecting and terminating
pregnancies with CAKUT could be higher among dia-
betic mothers in comparison with nondiabetic mothers,
and the exclusion of still births most likely leads to an
underestimation of the effect of diabetic pregnancies on
CAKUT. However, the literature suggests that antenatal
detection of CAKUT among women with and without
pre-gestational diabetes is similar.32 Therefore, the
underestimation of CAKUT from exclusion of termi-
nation of pregnancies could be nondifferential between
the diabetic and nondiabetic groups.
A further concern is that results may be explained
by other, unmeasured, variables (i.e., confounders
including BMI, maternal age, or intake of folic acid).
However, sensitivity analyses that attempted to
investigate the role of confounding did not identify
evidence that these variables would reduce the
strength of associations seen in this study.
This study has implications for maternal care during
pregnancy. A meta-analysis suggests that preconcep-
tion care is an effective intervention in reducing
congenital malformations.56 In Sweden, a prospective
nationwide study concluded that poor metabolic con-
trol in early pregnancy contributes to an increased risk
of fetal abnormalities.57 Fetal kidney development be-
gins in the first trimester, with an exponential increase
in nephrons occurring between 18 and 32 weeks of
gestation.58 Any policy that improves glycemic control
during this period may potentially reduce genitouri-
nary abnormalities.4 Pre-gestational diabetes can
remain undiagnosed, and screening among at-risk
women early in pregnancy provides an opportunity
to diagnose and improve glycemic condition in utero
during development, leading to improved outcomes.
In summary, this review raises the question of
whether maternal diabetes is a contributing factor for
incidence of CAKUT in both developed and developing
settings. If this association is confirmed, there is a po-
tential to improve kidney health by improving maternal
health and by preventing and diagnosing diabetes in a
timely manner in women of childbearing age.DISCLOSURE
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Table S1A. Quality assessment: rationale. This table
explains the conditions that helped classify articles as
having high/low risk of bias and confounding.
Table S1B. Case-control studies: quality assessment. This
table provides a detailed qualitative assessment of all
studies included in the review. All studies were assessed to
have high/low risk or uncertain risk of bias based on the
definitions set in Table S1A.
Table S1C. Cohort studies: quality assessment. This table
provides a detailed qualitative assessment of all cohort
studies included in the review. All studies were assessed
to have high/low risk or uncertain risk of bias based on
the definitions set in Table S1A.
Table S2A. In-depth analysis of confounding of all studies
included in meta-analysis. This table captures an in-depth
assessment of confounding factors that were adjusted and
not adjusted for all identified studies. The table ranks studies
as having residual cofounding and minimal confounding
only. Articles ranked as having minimal were combined in
sensitivity analysis that restricted meta-analysis only to those
studies that adjusted for confounding.
Table S2B. Assessment of Crude and reported OR used for
meta-analysis. This table describes if odds ratio or RRs for
studies were reported in the publication or manually calcu-
lated for this systematic review.For thosestudies that reported
both crude and adjusted OR, this table provides a side by side
comparison of the difference in crude and adjusted OR.
Figure S1. (A) Funnel plot of studies considered for meta-
analysis (RR of congenital genitourinary abnormalities
with all maternal diabetes): 14 studies that compare geni-
tourinary abnormalities in mothers with any diabetes types
and controls with no diabetes are plotted in the funnel
graph. The spread of studies here indicates minimal pub-
lication bias. (B) Funnel plot of studies considered for
meta-analysis (RR of congenital genitourinary abnormal-
ities with pre-existing diabetes): 18 studies that compare
genitourinary abnormalities in mothers with pre-
gestational diabetes and controls with no diabetes are
plotted in the funnel graph. The spread of studies here
indicates some publication bias. (C) Funnel plot of studies
considered for meta-analysis (RR of congenital genitouri-
nary abnormalities with gestational diabetes): 14 studies
that compare genitourinary abnormalities in mothers with
gestational diabetes and controls with no diabetes are
plotted in the funnel graph. The spread of studies here
indicates minimal publication bias.
Figure S2. (A) Forest plot of RR of congenital genitourinary
abnormalities with combined diabetes types (after
adjusting for confounding). Four studies comparing
congenital genitourinary abnormalities in any diabetes
type with control, nondiabetic women, and adjusted for691
CLINICAL RESEARCH M Parimi and D Nitsch: Diabetes During Pregnancy and CAKUTpotential confounding variables, are summarized. The
summary measure of association is RR, 1.56 (1.26–1.94).
(B) Forest plot of RR of congenital genitourinary
abnormalities with pre-existing diabetes (after adjusting
for confounding). Eight studies comparing congenital
genitourinary abnormalities in pre-existing diabetic
women with control, nondiabetic women, and adjusted for
potential confounding variables, are summarized above.
The summary measure of association is RR, 2.10 (1.75–
2.52). (C) Forest plot of RR of congenital genitourinary
abnormalities with gestational diabetes (after adjusting for
confounding). Seven studies comparing congenital geni-
tourinary abnormalities in gestational diabetic women with
control, nondiabetic women, and adjusted for potential
confounding variables, are summarized above. The sum-
mary measure of association is RR, 1.42 (1.22–1.54).
Figure S3. (A) Meta-analysis of studies that adjusted for
BMI as confounding factor with PGDM as exposure
(*hypospadias as genitourinary abnormality; **bilateral
agenesis and/or hypoplasia as urogenital abnormality).
Two studies were combined in this summary and the
summary measure of association is RR, 2.71 (0.77–9.59).
(B) Meta-analysis of studies that adjusted for BMI as con-
founding factor with GDM as exposure (*hypospadias as
genitourinary abnormality; **bilateral agenesis and/or
hypoplasia as urogenital abnormality). Two studies were
combined in this summary and summary measure of as-
sociation is RR, 1.50 (1.16–1.93).
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